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MM.CBA myeloid leukemia cell line did not block an effective 
GVL response, despite reducing lethal GVHD. These results 
demonstrate hat donor CD4+CD25 + T ceils infused early post- 
transplant can control the full development of GVItD without 
sacrificing asufficient GVL effect. 
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CD25 EXPRESSION DISTINGUISHES FUNCTIONALLY DISTINCT 
ALLOREACTIVE CD4+CDI34+ T CELL SUBSETS IN ACUTE GVHD 
Mazia'r.~, R.T.; Zhm~g, X.; Streete*', P.R. Medicine, OHSU, Port- 
land, OR. 
CD134 fOX40) is expressed on activated CD4+ donor T cells in 
antinals with aGVHD. Using a P--> FI rat BMT model of 
aGVHD, activated CD4+134+ T cells are shown to have a central 
role. These cells were evaluated, in vivo, using adoptive transfer. 
GVHD-associated donor CD4+134+ T cells were isolated from 
animals on D10, and the isolated cells were transferred to irradiat- 
ed (600R) F1 recipients with normal donor CD4-depleted CD8+ 
lymph node cells. This cell combination yielded lethal aGVHD in 
transplant recipients, while irradiated (600R) F1 control animals 
receiving either population alone failed to develop disease. Thus, 
aGVHD-associated CD4+134+ cells, as the only source of donor- 
derived CD4+ T cells, promote disease after adoptive transfer. 
However, in vitro challenge of the the aGVHD-associated 
CD4+134+ T cells with either host alloantigen or ConA provided 
only minimal proliferation. This T cell population was able to be 
stratified into CD25- and CD25+ subsets. CD4+134+25- T cells 
were selectively found in organized lymphoid tissues while 
CD4+134+25+ T cells were located in both organized lymphoid 
tissues and inflamed extralymphoid tissues. Although both 
CD4+134+ T cell subsets were observed throughout the disease 
course (D4 -->end stage), the CD4+134+25+ T subset predomi- 
nated on day 4. On D10, CD4+134+25- T cells proliferated to 
both ConA and allogeneic host leukocytes, while CD4+ 134+25 + T 
cells exhibited an anergic profile, with minimal response to either 
stimulus. Short-term culture of the CD4+134+25+ T cells to IL-2 
overcame T cell anergy, and cells recovered were alloresponsive. 
Thus, both CD4+ 134+ T cell subsets are comprised of alloreactive 
cells. When the anergic CD4+134+25+ T cells were added to 
responsive CD4+134+25- T cells, the CD4+134+25- cells no 
longer responded to antigen, indicating that CD4+134+25+ T 
cells inhibited the CD4+134+25- cell subset. The distinct issue 
localization, temporal induction and functional properties of these 
CD4+134+25- and CD4+134+25+ alloreactive T cell subsets ug- 
gest an unanticipated degree of complexity in the CD4+ T cell 
compartment in aGVHD. Clarification of the physiologic roles of 
the CD4+CD134+ subpopulations will provide insights into the 
temporal evolution of aGVHD. 
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T-CELL APOPTOSIS FOLLOWING NON-MYELOABLATIVE HEMATOPOI- 
ETIC CELL TRANSPLANTATION (HCT) 
Bhiis,~a~, FU; Si~lgleton, K.LS; LiTl, M.e; TabelliM, L.I; Fra~Tgoul, 
H.S; Damodaran, A.I; Hansen, ff.A. I i. Fred HlttchinsoJ~ Cai~cer 
Research Cellter, Seattle, WA; 2. National Taiwc.m UT~iversity, 
Taipei, TaiwaT~; 3. Vanderbih Unive~'sit~ Medical Ce~ter, 
Nashville, TN. 
We have previously demonstrated that PBMC from patients 
with aGVHD have high spontaneous'apoptosis following mye- 
loablative HCT. Short-term culture in the presence of dexam- 
ethasone or anti-CD3 monoclonfll antibody (Hum291) induces 
further apoptosis. We recently reported that monitoring sponta- 
neous; dexamethasone and anti-CD3 induced apoptosis may be 
useful for predicting steroid treatment outcome of GVHD in 
myeloablative HCT. We classified the outcome of steroid therapy 
into: (i)CR:complete response (no recurrence following steroid 
withdrawal) (ii)PR:partial/intermediate response(limited cGVHD, 
successfully withdrawn from immunosuppression) a d (iii) steroid 
dependent/refractory(SD/R): refractory GVHD or extensive 
GVHD requiring prolonged steroid/salvage therapy. Steroid 
dependent/refractory GVHD patients were very sensitive to anti- 
CD3 induced apoptosis after 4-weeks of steroid therapy. We now 
report our results in 25 patients undergoing non-myeloablative 
transplants. PBMC were obtained between day18-35 post-trans- 
plant and cultured for 24hours in medium and with Hum291 
(0.Sgg/ml). Apoptosis was measured by staining with 7AAD. In 
matched sibling donor transplants spontaneous apoptosis at day 
19-25 was 19.8+/-7.6% in 6 patients with aGVHD and 7.5+/- 
3.4% in 4 patients without any aGVHD(p<0.05) developing with- 
in 4 weeks of the assay. Spontaneous apoptosis was higher in URD 
transplants: 40.2+/-25.4% in 5 patients without aGVHD and 
I4.8+/-11.4% in 5 patients with aGVHD. GVHD requiring 
steroid therapy developed in 20 patients (10/14MSD, 10/11URD) 
between day 6-83 post-transplant (median 37.5 days). Assays were 
repeated after 4 weeks of steroid therapy. There was preferential 
anti-CD3 induced apoptosis in the SD/SR group(see table below). 
The pattern of apoptosis here is different from myeloablative 
transplantation, with an unexplained high spontaneous apoptosis 
in URD transplants without aGVHD. Preferential anti-CD3 
fuduced apoptosis occurs in non-myeloablative transplant patients 
who subsequently develop SD/SR GVHD. The correlation how- 
ever is not as strong, possibly due to other confounding factors 
including changing immune suppression i the non-myeloablative 
setting. 
Response Spontaneous Anti~CD3 p-value 
CR(n=4) 20.5+/7.9 23.4+/-8.1 NS 
PR(n=4) 11.7+/ 11.0 13.6+/-12.9 NS 
SD/SR(n=I2) 9.98+/-9.94 28.99+/9.9 ] <0.05 
I 
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THE LEUKEMIA-ASSOCIATED ANTIGEN PRI IS DERIVED FROM BOTH 
PROTEINASE 3 AND NEUTROPHIL ELASTASE PROTEINS 
OJ~o, Y.; St. ffohJ~, L.; Lu, S.; k~gl~g, C.; Mollch'em, ft. Blood & 
Marrow TraTz~Flantatio~, M. D. AJldersoTl Cancer Centre1", Hous- 
toTz, TX. 
PRI is an HLA-A2-restricted peptide leukemia-associated 
antigen that is contained within proteinase 3 (P3). We have 
shown that killing of leukemia cells by PRl-specific CTL corre- 
lates with P3 overexpression. However, the PR1 sequence is 
also contained within neutrophil elastase (NE), which is also 
aberrantly expressed in leukemia cells. To determine whether 
PR1 is processed and presented ffmn either protein, we used 
P3- and NE-transfected B cells as target cells in a proliferation 
assay with PRl-specific T cells. Full-length P3 and NE cDNA 
was cloned from the promyclocytic HL-60 cell line based on 
published sequences. The sequences were subcloned into an 
EGFP-containing vector (pCMS-EGFP) with a CMV promoter 
to drive constitutive xpression. The B cell line, HMy-CIR, 
previously stably transfected with the HLA-A*0201 gone, was 
transfected with P3-pCMS-EGFP and NE-pCMS-EGFP by 
electroporation for 24 hours. GFP expressing cells (P3- 
HMy.CIR-A2 and NE-HMy.CIR-A2, respectively) were select- 
ed by FACSorting and high transfection levels were confirmed 
by fluorescence microscopy. Quantitative real time PCR 
showed mRNA transcripts from one of two selected P3-trans- 
fected clones were only 2.6-fold less than HL-60 cells (p = 
0.07), and only 1.5-fold less in a second clone (p = 0.3). By con- 
trast, NE transcript numbers from a transfected clone were 7- 
fold.less than in HL-60 cells. Western blotting confirmed pro- 
tein expression in the NE-HMy.CIR-A2-transfected cells, 
although expression was similarly less than in HL-60 cells. 
PRl-specif ic CTL lines elicited from two healthy donors 
showed stimulation i dices (SI) of 1.3 and 2.4 When coincubated 
with P3-HMy.CIR-A2 target cells during BrDU incorporation, 
confirming that PR1-CTL recognize PR1 peptide processed 
and presented from P3. Interestingly, PR1-CTL also recog- 
nized NE-transfected cells, with SI of 1.5 and 2.1. No recogni- 
tion of non-transfectants or parent HMy.CIR (A2-) was 
observed. These results demonstrate that, in addition to P3, 
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PR1 is also processed and presented by NE, which may result in 
enhanced immunogenicity of the peptide conapared to peptides 
derived from a single protein. Redundancy of proteins may also 
lessen the impact of tumor loss variants after PRl-based 
immunotherapy. 
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TREATMENT OF DONORS WITH INTERLEUKIN-18 REDUCES ACUTE 
GRAFT-VERSUS-HOST DISEASE VIA STAT6 AND PRESERVES CD8 ÷ 
MEDIATED GRAFT-VERSUS-LEUKEMIA EFFECTS 
Reddy, p.t; Teshima, T.I; IJildebrandt, G J; ~(illiams, D.I; Liu, C?; 
Cooke, IvY; FeJv'ara, J.LJ 1. lnte~'nal Medicine, UMve1"sity of k/Iichi- 
gan Medical CeT~ter, Am7 A't'bor, MI; 2. Unive't'sity of Flo~'ida, 
GaineswTle, FL. 
haterleukin 18 modulates both Thl/Th2 responses and stimulates 
hcmatopoietic growth factor secretion. VVe investigated the effect of 
pretreating bone marrow transplant (BMT) donors with IL- 18 on the 
severity of acute GVHD using a well-characterized irradiated experi- 
mental BMT model (BALB/c(H-2d-~ B6 (H-2u). Pretreatment of 
allogeneic BMT donors with IL-18 (lpg/day of rmIL-18 for 10 days, 
day 11 to -1) significantly improved survival, and caused significant 
reduction in serum levels of TNF-c~(212 +18pgJml vs 524 +69pg/ml, 
P<0.05)and LPS (5.3 --1.1U/ml vs 12.4 _+l.3U/ml, P<0.05) and 
GVHD related intestinal histopathology (P<0.05). All surviving mice 
showed complete donor engTafunent, hus ruling out graft rejection 
and mixed chimerism as causes for decreased GVHD. IL-18 pretreat 
naent was also associated with reduced IFN- 7 (1987 -+387pg/ml vs 
4686 _+964p~ml, P<0.03) and greater IL-4 secretion (54.8 _+9.3pgkni 
vs 14.5 _+3.4pg/ml, P<0.04) by donor T cells after BMT. Surprisingly, 
when IFN-ydeficient 1nice were pretrcated with rmIL-18 and used as 
donors acute GVIID mortality was reduced thus ruling out the role 
of donor IFN-Tin this effect. Acute GVHD mortality was also 
reduced when IL-18 was administered to donors deficient in STAT4. 
Treannent of STAT6 deficient donors with IL-18 did not alter IFN- 
7 secretion (14.3 _+2.I ng/ml vs 10.2 _+3.8ng/mI, P=NS) or enhance 
IL-4 production. Furthermore pretreatment of STAT6-/ donors 
with IL-18 did not reduce acute GVHD mortality thus confirming 
the role of STAT6 signaling in IL-18's protective ffect. "eVe next 
investigated whether IL-18 can maintain a graft-versus-leukemia 
(GVL) effect using the same model and by injecting recipients with 
host-type (H-2 b) EL-4 MHC II-/-lymphoma cells at the time of 
BMT. IL-18 txeamlent did not alter donor CD8 + cytotoxic T lym 
phocyte (CTL) activity" and preserved graft versus leukemia (GVL) 
effects after allogeneic BMT (70% v I0%, P < 0.01). Our results 
demonstrate hat pretreatment of donors with IL-18 preserves the 
CD8 + mediated GVL effects but reduces acute GVHD in a donor 
derived IFN 3*independent but in a STAT6 dependent mechanism. 
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TACROLIMUS (FK-506) AND MYCOPHENOLATE MOFETIL (MMF) 
GVHD PROPHYLAXIS IN ALLOGENEIC SCT (ALLOSCT) RECIPIENTS: 
ALTERED MMF PHARMACOKINETICS (PK) ASSOCIATED WITH AGVHD 
BessT~es~:JTy, 0.; Ostmkwo, I.; Ha~v'ison, L.; Wolownik, K.; Wischhove'/', C.; 
Gatvin, ft.; Geo*ge, D.; Del Tovo, G.; Bradley, M.; Cairo, M.& CblTd'J'en's 
Hospital of New YoJ'k PT"esbyteHan, Columbia University, New York, NI( 
FK-506/NLMF is an effective salvage therapy for steroid-refrac- 
tory chronic (C) GVHD (Mookerjee t al, BMT 1999; 24:517-20) 
and has been used for prophylaxis of acute (A) and C GVHD fol 
lowing nonmyeloablative conditioning in adults (Rini BI et al, 
JCO 2002; 20:2017-203. We investigated safety and efficacy of 
FK-506/MMF regimen for GVHD prophylaxis to spare th use of 
methotrexate (MTX) and steroids in 29 pts (mean age 8.5 [range 
0.5-22 years]; 21 M, 8 F) undergoing 32 AlloSCT for hematologic 
malignancies (n=20), non-malignant disorders (n=7), and neurob- 
lastoma (n=2). GVHD prophylaxis included FK-506 0.03 
mg/kg/day continuous 1V on Day -1 or 1st day of conditioning 
plus MMF 15 mg/kg/dose PO/IV BID starting Day +1. Doses of 
FK-506 and MMF were adjusted to maintain concentrations with- 
in reference ranges of 5-20 ng/mL for FK-506 and 1-3.5 mcg/mL 
for mycophenoleic a id (MPA). HLA typing was serologic for A 
and B and high resolution DRB1. Stem cell sources were 6/6 
UCB (n=43, 5/6 UCB class I mismatch (n=4), 4/6 UCB (mismatch: 
class I [n=8], class II [n-l], double class I/II [n=3]), 6/6 related (R) 
BM (n=3), 6/6 RPBSCT (n=8), 5/6 RPBSCT class I mismatch 
(n=l). kanong 28 evaluable pts, mean days to ANC _>500/ram 3 x 2 
days was 14 (11-17) and 27 (8-70) following related RPBSCT/BM 
and UCB, respectively. Fifteen pts (53.6%) developed ->grade II
AGVHD: 7 RBM/PBSC and 8 UCB. The incidence of grade 
III/IV AGVHD was 32% (5 RBM/PBSC and 4 UCB) and 6% for 
CGVHD (n=2). FK-506/MMF was well tolerated, with 2 episodes 
of grade I I I - IV neurotoxicity (disorientation and leukoen- 
cephalopathy). M PA trough concentrations were monitored in the 
second half of the study (n=123. Eight pts developed AGVHD and 
7 bad MPA below target range (<1 mcg/ml) at GVHD onset. 
MMF doses >900 mg/m 2 IV/PO q6h (4 times standard ose) were 
required to achieve target MPA trough concentrations in the early 
AlloSCT period (< Day +30). Five of 12 pts monitored achieved 
target MPA levels before Day +30 and the incidence of >Grade III 
AGVHD was 20%. The estimated 1-year OS is 52.1%. These 
results uggest that FK506/MMF is a safe and effective MTX and 
steroid sparing GVHD prophylaxis regimen following R and 
UCB AlloSCT. Further pharmacokinetic and pharmacodynamic 
studies are ongoing in AlloSCT recipients to define the optimal 
dosing regimen of A~V[F. 
95 
CD83 ANTIGEN: A POTENTIAL NEW TARGET FOR GRAFT VERSUS 
HOST DISEASE PREVENTION 
Ml~7~steT; D.J.; Kato, J¥l.; 3/lacDo~ald, K.P., Rice, A.M.; Hart, D.N. 
Cance'r ]3iotheT~ap~, Mater Medical Researeh Institztte, Soath BvisbaTze, 
QLD, Aust1"alia. 
Novel strategies are required to overcome the limitations imposed 
on hematopoietic stem cell transplantation by graft versus host dis- 
ease (GVHD). Cm'rent GVHD therapies focus on elimination or 
attenuation f the effcctor T cell. There is emerging evidence in the 
literature to suggest a primary role for dendritic ells (DC) in the 
initiation of GVHD. CD83 is a marker of DC differentiation/activa- 
tion. Polyclonal anti-CD83 antibody (RA83) inhibits the T lympho- 
cyte proliferative response in the mkxed leukocyte reaction (MLR) 
stinmlated by allogeneic monocyte derived DC (MoDC). We inves- 
tigated the mechanism of tltis RA83 mediated immunosuppression 
and found that it was not due to functional blockade of CD83. It 
required the presence of NK-cclls, Fab fragments of RA83 did not 
inhibit the MLR, and treatment with an Fc7 receptor III (CD16) 
blocldng monoclonaI antibody (3G8) prevented the blockade, indi- 
cating that it was due to antibody dependent cellular cytotoxicity 
(ADCC) of CD83 + cells. In additional experiments we showed that 
activated NiL<ells lyse 5/~Cr labelled CD83 + MoDC in the presence 
of RA83, but not in the presence of non-immune polyclonal anti- 
body. hnmamre CD83 MoDC were not lysed in the presence of 
RA83. However, lysis of MoDC did not account for all the effect 
because stimulation with allogeneic MoDC fixed with paraformalde- 
hyde also exhibited inhibition of T lymphocyte proliferation i  the 
presence of RA83. This implied that CD83 + targets of ADCC must 
exist or arise in the responder cell preparation. YVe then established 
that activated blasting T<ells (CD25 +, Ki67 +) stimulated by allo- 
geneic MoDe also express CD83 and that they become targets of 
NK-cell mediated ADCC. Thus, CD83 is expressed by both stimu- 
lator and responder cells in the MLR. Simultaneous targeting of 
both activated cell populations by a single reagent such as anti- 
CD83 may be a potent means of achieving therapeutic imnmnosup- 
pression for allogeneic hematopoietic stem cell transplantation. 
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IMPROVED OUTCOME IN ACUTE LETHAL MURINE GRAFT VERSUS 
HOST DISEASE (GVHD) FOLLOWING ADMINISTRATION OF THE PRO- 
TEASOME INHIBITOR PS-341 
Webziak, L.AJ; &m, K.2; Sayevs, T.J.2; Mzlrpby, I4~J. l I. Microbiolo- 
gy, University of Nevada, Rent, Rent, NV; 2. SAIC-t;rederick, Freder- 
ick, 3lID. 
Proteasome inhibitors have recently shown much promise by 
selectively acting on various neoplastic ells, particularly" myelo- 
mas. We have recently found that the use of proteasome inhibi- 
tion with PS-34I sensitizes neoplastic ells to TRAIL mediated 
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